Alnylam Pharmaceuticals

Avidity Biosciences

Natera

Veracyte

Illumina

Bio-Techne

Ultragenyx Pharmaceutical

Agilent Technologies

Sarepta Therapeutics

CRISPR Therapeutics

Global X Genomics & Biotechnology ETF

GNOM tracks an index of global biotech equities, selected and weighted by market cap.

Editas Medicine

Intellia Therapeutics

Gene editing is revolutionizing medicine, creating substantial opportunities for some of the best gene editing stocks. With the technology, we can fix faulty genes, or replace them with healthier genes in an attempt to cure diseases or help the body fight disease.

The 3 Best Gene Editing Stocks to Buy in July 2024

Twist Bioscience Corp

Genomics is the future of medicine. With it, companies are racing to shed light on human health and disease.

Genomics Game-Changers: 3 Stocks Unlocking the Secrets of Life

Metagenomi Inc

Pay close attention to gene editing stocks. By 2028, according to MarketsandMarkets, the market could be worth about $10.6 billion from $5.3 billion in 2023.

3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire

GNMO invests across companies benefiting from advancements in the field of genomics within biotechnology. The fund's historical performance has been poor amid volatile stock prices for underlying holdings. Genomics may be the future, but still missing a blockbuster application to drive a wave of bullish momentum into the segment.

GNOM: Genomics Still Waiting For Its 'ChatGPT' Moment

Verve Therapeutics

Gene editing could revolutionize how millions of patients are treated all over the world. That could create big opportunities for some of the most exciting gene-editing stocks.

3 Stocks That Could Be the Next Big Thing in Gene Editing

Gene editing is revolutionizing medicine. For example, just weeks ago, the U.S. Federal Drug Administration approved a new gene-editing treatment for sickle cell disease and transfusion-dependent beta-thalassemia, a genetic disorder that prevents the production of hemoglobin in the blood and requires regular blood transfusions.

3 Gene Editing Stocks With Unprecedented Surge Potential

Some of the top gene-editing stocks have had immense surge potential. Look at CRISPR Therapeutics (NASDAQ: CRSP ), for example.

3 Once-in-a-Lifetime Gene Editing Stocks with Unprecedented Surge Potential

Alerian MLP ETF

ARK Genomic Revolution Multi-Sector ETF

Amplify Lithium & Battery Technology ETF

VanEck Vectors Biotech ETF

SPDR Bloomberg 1-3 Month T-Bill ETF

PIMCO Active Bond ETF

Amplify Seymour Cannabis ETF

Global X Autonomous & Electric Vehicles ETF

Alerian Energy Infrastructure ETF

First Trust Global Wind Energy ETF

iShares Core High Dividend ETF

iShares Nasdaq Biotechnology ETF

iShares Global Clean Energy ETF

iShares Core S&P Small Cap ETF

iShares U.S. Home Construction ETF

iShares Russell 2000 ETF

Adasina Social Justice All Cap Global ETF

KraneShares Electric Vehicles & Future Mobility Index ETF

KraneShares Global Carbon ETF

Global X Lithium & Battery Tech ETF

PIMCO Enhanced Short Maturity Active ETF

Invesco Dynamic Building & Construction ETF

First Trust NASDAQ Clean Edge Green Energy Index Fund

Invesco S&P 500 Equal Weight ETF

Good morning, VettaFi Voices! We are a week out from the VettaFi 2024 Market Outlook Symposium on December 14, which will feature a range of ETF industry leaders discussing their expectations for different areas of the financial markets and the economy in 2024.

VettaFi Voices On: The Outlook for 2024

Gene editing is revolutionizing how the world approaches medicine. In fact, by “simply” removing cells from the body, editing them, and reintroducing them, we could help treat sickle-cell anemia, cancers, blood disorders, blindness, cystic fibrosis, and even muscular dystrophy if all goes according to plan.

3 Gene Editing Stocks to Generate Super-Charged Gains

This article provides a dashboard with industry metrics in healthcare, then focus on the Global X Genomics & Biotechnology ETF. Pharmaceuticals/biotechnology and healthcare providers have fair value and quality scores. Healthcare equipment is the most overvalued subsector.

Healthcare Dashboard For August And Focus On GNOM

GNOM is a $200 million ETF that invests in a forward-looking set of innovative businesses focused on the genomics industry. This is a long-term growth area, but it will need to get more profitable to get more popular. That could take a little while.

GNOM: A Genomics ETF That Will Have Its Day, Even If Not Right Now

CRISPR could revolutionize the way we treat thousands of diseases. Currently, there are about 7,000 caused by genetic disorders, which occur when a mutation affects your genes, or when you have the wrong amount of genetic material, as noted by the Cleveland Clinic.

The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket

Loncar Cancer Immunotherapy ETF

iShares Genomics Immunology and Healthcare ETF

ALPS Medical Breakthroughs ETF

SPDR S&P Biotech ETF

Amid the trying circumstances in the market right now, investors may be well served to target the best biotech ETFs to buy. Fundamentally, these exchange-traded funds benefit from permanent relevance.

The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector

Gene editing stocks present themselves as one of the more lucrative investments in the healthcare sector. Gene editing, a revolutionary take on the science of genetic engineering, has the potential to countless lives around the globe.

3 Gene Editing Stocks With the Best Long-Term Potential

ARK Innovation ETF

Amplify Mobile Payments ETF

Cathie Wood, famous for the success of Ark Investment???s winning products, had faced a miserable fate in 2022.

Will 2023 be the Year of Cathie Wood ETFs?

Pharmaceuticals and biotechnology have the best value and quality scores in the sector. Healthcare providers are close to their historical baseline in valuation and quality.

GNOM: Healthcare Dashboard For January

The Global X Genomics & Biotechnology ETF tracks the Solactive Genomics Index. It invests in genomics and biotechnology companies. The fund is highly concentrated in one industry, which can negatively affect its performance.

GNOM: Get Exposure To The Latest Genomics And Biotechnology Companies

CRISPR could revolutionize the way we treat thousands of diseases.  Many of these diseases occur when mutations affect genes, or when people have the wrong amount of genetic material,  the Cleveland Clinic reported.

3 CRISPR Stocks That Will Make You Filthy Rich in 10 Years

Global X Longevity Thematic ETF 

Virtus LifeSci Biotech Clinical Trials ETF

Virtus LifeSci Biotech Products ETF

BlackRock Future Health ETF

Principal Healthcare Innovators Index ETF

Global X Telemedicine & Digital Health ETF

First Trust NYSE Arca Biotechnology Index Fund

Fidelity MSCI Health Care ETF

First Trust Nasdaq Pharmaceuticals ETF 

First Trust Health Care AlphaDEX Fund

Amplify Treatments Testing & Advancements ETF

 Franklin Genomic Advancements ETF

ROBO Global Healthcare Technology and Innovation ETF

Invesco Nasdaq Biotechnology ETF

iShares U.S. Pharmaceuticals ETF

iShares U.S. Healthcare Providers ETF

iShares U.S. Medical Devices ETF

iShares Global Healthcare ETF

iShares U.S. Healthcare ETF

Eli Lilly

Global X Longevity Thematic ETF

First Trust Indxx Medical Devices ETF

Merck

Novo Nordisk

Invesco Dynamic Biotechnology & Genome ETF

Direxion Daily Pharmaceutical & Medical Bull 3X Shares

Simplify Health Care ETF

Invesco Dynamic Pharmaceuticals ETF

VanEck Vectors Pharmaceutical ETF

Invesco S&P SmallCap Health Care ETF

Invesco DWA Healthcare Momentum ETF

Invesco S&P 500 Equal Weight Health Care ETF

Vanguard Health Care ETF

Wisdomtree BioRevolution Fund

SPDR S&P Health Care Equipment ETF

SPDR S&P Health Care Services ETF

Health Care Select Sector SPDR Fund

SPDR S&P Pharmaceuticals ETF

How a recession could impact health care stocks in 2023. As Covid continues, what it could mean for the health care sector.

Can Health Care Stocks Outperform Again In 2023?

Pharmaceuticals and biotechnology have the best value and quality scores. Healthcare providers look undervalued relative to 11-year averages.

GNOM: ETF Review And Healthcare Dashboard For October

Biotechnology was a much sought-after sector following the pandemic, but it's been having to adjust to a new normal since. Still, the sector offers growth potential as new and innovative biotechnology develops with more investment.

As Biotech Adjusts to “New Normal,” Get Exposure With This ETF

ProShares Ultra Nasdaq Biotechnology

iShares Neuroscience And Healthcare ETF

Recognition that aging populations will give rise to new healthcare needs and heightened awareness of mental health issues are bringing renewed focus to neurological health. Recent advances in genomics and immunology, new diagnostics and surgeries, and reductions in stigma associated with mental health are unlocking radical progress in neuroscience this decade akin to the genomics revolution of the past two decades.

Why Now Could Be The Time To Consider Neuroscience Investments

Beam Therapeutics

Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.

A Comprehensive Guide to Genomic ETFs

iShares Evolved U.S. Innovative Healthcare ETF

Pharma and biotech ETFs are in great shape and are trading at a one-month high level.

Pharma & Biotech ETFs at One-Month High: Here's Why

GNOM lacks efficient portfolio reshuffling and may not be able to gain from higher alpha-producing stocks in the near future.

GNOM: Poor Historical Performance, Lack Of Focus, Uncertain Future

News for Global X Genomics & Biotechnology ETF ETF (GNOM)